|
Scancell Holdings PLC on Friday confirmed it was in advanced talks to acquire Neuphoria Therapeutics Inc, which could facilitate a Nasdaq listing. Scancell, an Oxford-based pharmaceutical company focused on cancer immunotherapies, said the talks are regarding a potential reverse merger transaction, whereby it would buy Nasdaq-listed biotechnology firm Neuphoria via an all-share transaction. The acquisition could increase Scancell’s profile with US specialist investors, the firm said. Scancell added: ‘Concurrently, Scancell is in discussions regarding possible equity and debt financing to support a planned global phase 3 registrational study for its lead asset, iSCIB1+.’ Sancell explained: ‘iSCIB1+, the lead product from their DNA ImmunoBody platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a phase 2 trial in melanoma.’ The company does not expect that the potential transaction would constitute a reverse takeover under London AIM market rules. It added that there can be no certainty that a firm agreement with Neuphoria will be reacted. Scancell shares fell 4.0% to 18.25 pence each on Friday afternoon in London, while Neuphoria shares opened 2.1% lower at $4.27 each in New York. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
